Standout Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carci... 1990 2026 2002 2014 3.6k
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (2006)
    James A. Bonner, Paul M. Harari et al. New England Journal of Medicine
  2. Paclitaxel (Taxol) (1995)
    Eric K. Rowinsky, Ross C. Donehower New England Journal of Medicine
  3. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival (2009)
    James A. Bonner, Paul M. Harari et al. The Lancet Oncology
  4. Taxol: A Novel Investigational Antimicrotubule Agent (1990)
    Eric K. Rowinsky, Lorraine A. Cazenave et al. JNCI Journal of the National Cancer Institute
  5. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer (2004)
    Román Pérez-Soler, Abraham Chachoua et al. Journal of Clinical Oncology
  6. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies (2001)
    Manuel Hidalgo, Lillian L. Siu et al. Journal of Clinical Oncology
  7. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (2006)
    Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology
  8. ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial (2002)
    Malcolm Ranson, Lisa A. Hammond et al. Journal of Clinical Oncology
  9. THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS (1997)
    Eric K. Rowinsky Annual Review of Medicine
  10. The Current Status of Camptothecin Analogues as Antitumor Agents (1993)
    William J. Slichenmyer, Eric K. Rowinsky et al. JNCI Journal of the National Cancer Institute
  11. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) (2003)
    George W. Sledge, Donna Neuberg et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 128 standout
Sub-graph 1 of 17

Citing Papers

Polymeric Nanoparticles for Drug Delivery
2024 Standout
Head and Neck Cancer
2020 Standout
29 intermediate papers

Works of Eric K. Rowinsky being referenced

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2009 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
and 12 more

Author Peers

Author Last Decade Papers Cites
Eric K. Rowinsky 18262 11946 9456 392 31.5k
Lillian L. Siu 11372 8050 6417 570 24.0k
Waun Ki Hong 12563 16651 7980 505 33.5k
Fadlo R. Khuri 9771 14495 5510 478 26.6k
Jennifer R. Grandis 9884 10189 4844 341 21.5k
José Baselga 25287 19503 13824 482 45.7k
Everett E. Vokes 18801 9449 15215 767 35.5k
Quynh‐Thu Le 7641 6656 6769 453 24.8k
Corey J. Langer 17063 5718 16729 556 27.9k
Grant A. McArthur 14701 14988 5248 388 26.3k
Jacek Jassem 11155 4695 7771 510 19.3k

All Works

Loading papers...

Rankless by CCL
2026